Previous 10 | Next 10 |
Ultragenyx (NASDAQ: RARE ) inks an agreement with Daiichi Sankyo ( OTCPK:DSKYF ) for its proprietary AAV-based gene therapy manufacturing technologies. More news on: Ultragenyx Pharmaceutical Inc., Daiichi Sankyo Company, Limited, Daiichi Sankyo Company, Limited, Healthcare stocks news, ...
Daiichi Sankyo granted non-exclusive license to Ultragenyx HeLa manufacturing platform Ultragenyx to receive $200 million upfront, including $125 million in cash and $75 million via equity investment NOVATO, Calif., March 31, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc....
REGENXBIO (NASDAQ: RGNX ) inks an agreement with Ultragenyx (NASDAQ: RARE ) aimed at developing a gene therapy for an undisclosed rare metabolic disorder. More news on: REGENXBIO Inc., Ultragenyx Pharmaceutical Inc., Healthcare stocks news, Read more ...
- REGENXBIO grants Ultragenyx exclusive, worldwide rights to NAV AAV8 and AAV9 Vectors for the development and commercialization of gene therapy treatments for a rare metabolic disorder - Agreement for use of NAV Vectors expands ongoing relationship between Ultragenyx and REGENXBIO RO...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
SARASOTA, Fla. and NOVATO, Calif., March 16, 2020 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, today ...
NOVATO, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Shalini Sharp, the company's Chief Financial Offi...
NOVATO, Calif. and TOKYO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: ...
NOVATO, Calif., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Tom Kassberg, the company’s Chief Business ...
Image source: The Motley Fool. Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Q4 2019 Earnings Call Feb 13, 2020 , 5:00 p.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million Reaffirmed 2024 expected total revenue guidance between $500 million to $530 million, Crysvita revenue of $375 million to $400 million, and Dojolvi revenue of $75 ...
NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today released its 2023 Corporate Responsibility Report, which showcases the company’s efforts to transform the lives of individuals and families impacted by rare and ultrarare diseases, empowe...
NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that all patients have been enrolled across the Phase 3 Orbit and Cosmic studies evaluating setrusumab (UX143) in pediatric and young adult patients with osteogenesis imperfect...